New immune therapy tested to keep aggressive breast cancer in check

This study tested whether the immunotherapy drug pembrolizumab could help control advanced inflammatory or triple-negative breast cancer in patients whose disease had already responded to or stabilized with chemotherapy. The trial involved 71 participants with these aggressive forms of breast cancer that had spread or returned. Researchers aimed to see if boosting the immune system could prevent cancer progression in patients who were already showing some response to treatment.